|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN, USA
2 Diabetes Research and Training Center, Vanderbilt University, Nashville, TN, USA
3 Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN, USA; Diabetes Research and Training Center, Vanderbilt University, Nashville, TN, USA
* To whom correspondence should be addressed. E-mail: stephanie.m.gustavson{at}vanderbilt.edu.
Epinephrine increases net hepatic glucose output (NHGO) mainly via increased gluconeogenesis, while glucagon increases NHGO mainly via increased glycogenolysis. The aim of the present study was to determine how the two hormones interact in controlling glucose production. In 18-h fasted conscious dogs a pancreatic clamp initially fixed insulin and glucagon at basal levels, following which one of four protocols was instituted. In G+E glucagon (1.5 ng/kg/min; portally) and epinephrine (50 ng/kg/min; peripherally) were increased, in G glucagon was increased alone, in E epinephrine was increased alone, and in C neither were increased. In G, E, and C, glucose was infused to match the hyperglycemia seen in G+E (~250 mg/dl). The areas under the curve for the increase in NHGO, after subtracting the change in C, were as follows: G=661±185, E=424±158, G+E=1178±57 mg/kg. Therefore, the overall effects of the two hormones on NHGO were additive. Additionally, glucagon exerted its full glycogenolytic effect while epinephrine exerted its full gluconeogenic effect, such that both processes increased significantly during concurrent hormone administration.
This article has been cited by other articles:
![]() |
S. M. Breckenridge, B. Raju, A. M. Arbelaez, B. W. Patterson, B. A. Cooperberg, and P. E. Cryer Basal insulin, glucagon, and growth hormone replacement Am J Physiol Endocrinol Metab, November 1, 2007; 293(5): E1303 - E1310. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Everett-Grueter, D. S. Edgerton, E. P. Donahue, S. Vaughan, C. A. Chu, D. K. Sindelar, and A. D. Cherrington The effect of an acute elevation of NEFA concentrations on glucagon-stimulated hepatic glucose output Am J Physiol Endocrinol Metab, September 1, 2006; 291(3): E449 - E459. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Moore, C. A. DiCostanzo, D. Dardevet, M. Lautz, B. Farmer, and A. D. Cherrington Interaction of a selective serotonin reuptake inhibitor with insulin in the control of hepatic glucose uptake in conscious dogs Am J Physiol Endocrinol Metab, March 1, 2005; 288(3): E556 - E563. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Guy, D. Sandoval, M. A. Richardson, D. Tate, P. J. Flakoll, and S. N. Davis Differing physiological effects of epinephrine in type 1 diabetes and nondiabetic humans Am J Physiol Endocrinol Metab, January 1, 2005; 288(1): E178 - E186. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. C. Connolly, L. N. Aglione, M. S. Smith, D. B. Lacy, and M. C. Moore Pregnancy impairs the counterregulatory response to insulin-induced hypoglycemia in the dog Am J Physiol Endocrinol Metab, September 1, 2004; 287(3): E480 - E488. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Hornbuckle, C. A. Everett, C. C. Martin, S. S. Gustavson, C. A. Svitek, J. K. Oeser, D. W. Neal, A. D. Cherrington, and R. M. O'Brien Selective stimulation of G-6-Pase catalytic subunit but not G-6-P transporter gene expression by glucagon in vivo and cAMP in situ Am J Physiol Endocrinol Metab, May 1, 2004; 286(5): E795 - E808. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Gustavson, C. A. Chu, M. Nishizawa, B. Farmer, D. Neal, Y. Yang, S. Vaughan, E. P. Donahue, P. Flakoll, and A. D. Cherrington Glucagon's actions are modified by the combination of epinephrine and gluconeogenic precursor infusion Am J Physiol Endocrinol Metab, September 1, 2003; 285(3): E534 - E544. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |